LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

30.71 0.36

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

30.18

Максимум

30.83

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-2.78% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	794M 3.2B
Предишно отваряне	30.35
Предишно затваряне	30.71

Настроения в новините

By Acuity

57%

43%

322 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.11.2025 г., 16:56 ч. UTC

Печалби

Значими двигатели на пазара

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

25.11.2025 г., 21:38 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:31 ч. UTC

Пазарно говорене

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25.11.2025 г., 21:27 ч. UTC

Печалби

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25.11.2025 г., 21:20 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:18 ч. UTC

Печалби

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25.11.2025 г., 21:15 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 20:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25.11.2025 г., 18:42 ч. UTC

Пазарно говорене

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25.11.2025 г., 18:25 ч. UTC

Придобивния, сливания и поглъщания

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25.11.2025 г., 17:30 ч. UTC

Пазарно говорене

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Financial Details Weren't Disclosed

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25.11.2025 г., 16:32 ч. UTC

Придобивния, сливания и поглъщания

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25.11.2025 г., 16:31 ч. UTC

Придобивния, сливания и поглъщания

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25.11.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25.11.2025 г., 16:23 ч. UTC

Печалби

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25.11.2025 г., 16:12 ч. UTC

Пазарно говорене

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25.11.2025 г., 16:11 ч. UTC

Пазарно говорене

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Sterling Could Briefly Rise After Budget -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

-2.78% надолу

12-месечна прогноза

Среден 28.67 USD -2.78%

Висок 32 USD

Нисък 21 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

322 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.